Search
forLearn
5 / 801 resultsResearch
5 / 1000+ results
research LncRNA-miRNA-mRNA regulatory networks in skin aging and therapeutic potentials
ceRNA networks offer potential treatments for skin aging and wound healing.
research Recent advances in exosomal non‐coding RNA‐based therapeutic approaches for photoaging
New treatments for skin damage from UV light using stem cells and their secretions show promise for skin repair without major risks.
research LncRNA RP11-818O24.3 promotes hair-follicle recovery via FGF2-PI3K/Akt signal pathway
research LncRNA RP11-818024.3 Promotes Hair-Follicle Recovery Via FGF2-PI3K/Akt Signal Pathway
LncRNA RP11-818024.3 helps hair growth and recovery in hair loss by boosting cell survival and reducing cell death.
research POSTTEST: EXPIRATION DATE: OCTOBER 2011
Community Join
5 / 1000+ resultscommunity Black market pp405? Title title
PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.
community PP405 is NOT gray market jxl069
PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.
community Grey Market GT20029 and Frequency of Application
The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.
community A warning to anyone considering 3rd party sourcing PP405 or its analogs
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.
community Shiseido RCH-01
Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.